Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure. | Cost Effectiveness and Resource Allocation BioMed Central Research Open Access Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure Franz P Hessel Address Institute for Health Care Management University of Duisburg-Essen Campus Essen Schutzenbahn D-45127 Essen Germany Email Franz P Hessel - Corresponding author Published 05 October 2006 Received 27 March 2006 Accepted 05 October 2006 Cost Effectiveness and Resource Allocation 2006 4 16 doi 1478-7547-4-16 r This article is available from http content 4 1 16 2006 Hessel licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Acute-on-chronic liver failure ACLF is a life threatening acute decompensation of a pre-existing chronic liver disease. The artificial liver support system MARS is a new emerging therapeutic option possible to be implemented in routine care of these patients. The medical efficacy of MARS has been demonstrated in first clinical studies but economic aspects have so far not been investigated. Objective of this study was to estimate the cost-effectiveness of MARS. Methods In a clinical cohort trial with a prospective follow-up of 3 years 33 ACLF-patients treated with MARS were compared to 46 controls. Survival health-related quality of life as well as direct medical costs for in- and outpatient treatment from a health care system perspective were determined. Based on the differences in outcome and indirect costs the cost-effectiveness of MARS expressed as incremental costs per life year gained and incremental costs per QALY gained was estimated. Results The average initial intervention costs for MARS were 14600 EUR per patient .
